VYNE's YB-101 Enters Phase 2 for Graves' Disease, Secures $200M Funding Through 2028
VYNE has more than doubled off its 52-week low of $0.281.
Summary
VYNE Therapeutics is advancing its lead drug candidate, YB-101, into a Phase 2a/2b trial for Graves' disease in Q2 2026. This follows earlier S-4 filings detailing the reverse merger with Yarrow Bioscience. The company has secured $200 million in financing, a massive capital injection relative to its market cap, providing a cash runway into 2028. Advancing a drug to Phase 2 is a critical de-risking milestone for a biotech. Top-line Phase 2a data for YB-101 is anticipated in H2 2027.
At the time of this announcement, VYNE was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.6M. The 52-week trading range was $0.28 to $1.96. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.